- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Case 2: Male, 58 Years Old with AD
Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.
Panelists:
Omar Noor, MD, FAAD
Rao Dermatology
Atlantic Highlands, New Jersey
Program Description:
Omar Noor, MD, FAAD, provides insights from a case-based discussion, wherein he navigates the complexities surrounding patient care, emphasizing the critical importance of patient education, trust-building, and equitable access to care. He also explores the nuanced implications of boxed warnings linked to JAK inhibitors, drawing attention to variations between systemic and oral forms of topical ruxolitinib, and their potential influence on dialogues with patients and fellow healthcare providers.
Segment Description:
Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.
